Why the study?
The review aims to introduce internists to a new Russian-developed fixed-dose combination of ramipril and indapamide (Concealar-D24) for the treatment of arterial hypertension.
The review highlights a new Russian-developed fixed-dose combination of ramipril and indapamide for managing arterial hypertension and cardiovascular diseases.
The review is devoted to introducing a wide range of internists to the new fixed combination of ramipril and indapamide (Concealar-D24), created by Russian scientists. This is the first original domestic development for the treatment of arterial hypertension, which is successfully produced by the first Russian resident of the special economic zone, the pharmaceutical plant «VERTEX» in St. Petersburg. The advantage of Concealar-D24 is a rational combination of two drugs that have not only antihypertensive and organoprotective effects, but also a large convincing base of research on their impact on the prognosis of life in patients with cardiovascular diseases: arterial hypertension, coronary heart disease, heart failure.
No takes yet. Share an insight, caveat, or question.
N. Yu. Borovkova (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: